Phase 1/2Terminated

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer

Sponsor
Helix BioPharma Corporation (Industry)
Enrollment
28 enrolled
Conditions
Pancreas Cancer
Interventions
L-DOS47; Doxorubicin
Ages
adults, older adults
Registry
NCT04203641

Full record on ClinicalTrials.gov

From the registry

This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

Primary outcomes

  • Number of complete plus partial responders as per RECIST version 1.1
  • Adverse events (as per CTCAE v. 5.0)

History

  1. Last registry update

  2. Primary completion

  3. Registered

  4. Started